



# Second Announcement

## 16th International Pulmonary Hypertension Forum

### **MAKING TIMELY DECISIONS IN PAH**

**Austria Center Vienna  
Vienna, Austria | 10 – 12 March 2017**

**Scientific Committee:  
Professor Marius M. Hoeper  
Professor Lewis Rubin**

**Professor Nazzareno Galiè  
Professor Vallerie McLaughlin  
Professor Gérald Simonneau**



## Dear Colleague,

Over recent years, our increasing understanding and experience in managing pulmonary arterial hypertension (PAH) has led to incremental improvements in outcomes for patients with this progressive disease.

Given the aggressive and chronic nature of PAH, the availability of new treatment options and strategies, such as initial combination therapy, that have been shown to improve long-term outcomes represents one of the key advances in the current era of PAH. In addition to these advances in therapeutic management, the impact of PAH on patient quality of life has increasingly been under the spotlight and there is an intensifying effort to focus on how this can be assessed, and whether this impact on patients can be reduced.

The 16th International Pulmonary Hypertension Forum, organised by Actelion Pharmaceuticals Ltd, will provide a comprehensive update on the long-term management of PAH, including recent data to support advanced therapies and different therapeutic strategies, as well as ways of optimising general care to address the heavy burden that PAH has on the lives of patients. There will be multiple case-based learning opportunities as well as ample opportunity to discuss key issues and topics with renowned experts, including those that have been involved in some of the pivotal PAH trials and the authors of the international ESC/ERS treatment guidelines for PAH. Following the success of last year's Forum, a dedicated nurse programme will be included once again, which reflects the important role that specialist nurses play in the daily management of PAH patients as well as the growing need to understand the disease from the perspective of patients and their caregivers.

This two-day meeting offers a valuable opportunity to network with colleagues and international experts in the field of PH. Now in its 16th year, the International PH Forum continues to be the worldwide renowned platform to discuss the current status and future developments in PAH, reflecting Actelion's ongoing commitment and drive to further advance the field of PAH.



Prof. Nazzareno Galiè



Prof. Marius M. Hoeper



Prof. Vallerie McLaughlin



Prof. Lewis Rubin



Prof. Gérald Simonneau

**Saturday, 11 March 2017**

**09:00–10:50 Plenary 1:**

**Managing risk and optimising management in PAH**

**Co-Chairs:  
I Lang, L Rubin**

- PAH in 2017 – Time to reflect
- Assessing and controlling disease progression
- Deciding on the right treatment strategy
- Triple combination therapy in practice – Experience from Ann Arbor

MM Hoeper  
S Gaine  
M Humbert  
V McLaughlin

*10:50 – 11:20 Coffee break with poster exhibition*

**11:20 – 12:40 Plenary 2:**

**Assessing PAH in the clinic**

**Co-Chairs:  
S Bartolome, G Simonneau**

- Translating theory into clinical practice – An interactive patient case
- Haemodynamic assessment – You need to get it right!
- Assessing the “feels and functions”

M Palazzini  
S Rosenkranz  
I Preston

*12:40 – 14:15 Lunch*

**14:15 – 15:30 Parallel breakout sessions:**

**Moving forward – Addressing challenges in PAH**

**Co-Chairs:**

**Case-based learning**

**S Bartolome  
H Gu**

- G Coghlan, K Dimopoulos, A Seferian

**A focus on the “right” ventricle in PAH**

**Y Adir  
N Galiè**

- S Chan, J Granton, A Vonk Noordegraaf

**Understudied forms of PAH**

**S Harari  
H Olschewski**

- D Montani, G Simonneau, R Souza

**14:15–15:30 Cardiac MRI workshop**

- D Kiely, M Simon

**Special registration required**

*15:30 – 15:45 Switching rooms & coffee break*

## 15:45 – 17:00 Parallel breakout sessions:

### Tackling a multifaceted disease

**Co-Chairs:**

#### Management of CTEPH

- N Galiè, X Jaïs, T Ogo

**M Delcroix  
G Simonneau**

#### PAH-CHD – Managing the spectrum of diseases

- F Berger, G Diller, A Manes

**M Beghetti  
M Gatzoulis**

#### Transplantation in PAH – An important option for patients with advanced disease

- H Gall, TBC, TBC

**MM Hoepfer  
W Klepetko**

## 15:45 – 17:00 RHC workshop

- I Lang, A Torbicki

**Special registration required**

**Sunday, 12 March 2017**

## 09:00 – 10:30 Plenary 3:

### PAH therapy – Available options and future perspectives

**Co-Chairs:**

**N Galiè, L Howard**

- Interactive patient case – What would you do?
- Optimising management of PAH – 2017 and beyond
- Actelion's commitment to PAH – The next 10 years

**D Dumitrescu  
O Sitbon  
M Clozel**

*10:30 – 11:00 Coffee break with poster exhibition*

## 11:00 – 12:20 Plenary 4:

### Highlights from the PAH world

**Co-Chairs:**

**N Kim, JL Vachiéry**

- In focus – The paediatric PAH population
- The year in review
- Highlights from the Nurse Programme
- Highlights of the PH Forum 2017

**M Beghetti  
A Ghofrani  
W Gin-Sing  
R Channick**

*12:20 – 14:15 Lunch*

### Abstract submission:

**Participants are invited to contribute to the scientific programme by submitting abstracts for poster display by Friday, 20 January 2017.**

# PH Forum Vienna, Austria | 10 – 12 March 2017

## Forum Faculty

<b>Yochai Adir</b> Haifa, Israel	<b>Sean Gaine</b> Dublin, Ireland	<b>Xavier Jaïs</b> Le Kremlin-Bicêtre, France	<b>Stephan Rosenkranz</b> Cologne, Germany
<b>Sonja Bartolome</b> Dallas, USA	<b>Nazzareno Galiè</b> Bologna, Italy	<b>David Kiely</b> Sheffield, UK	<b>Lewis Rubin</b> New York, USA
<b>Maurice Beghetti</b> Geneva, Switzerland	<b>Henning Gall</b> Giessen, Germany	<b>Nick Kim</b> La Jolla, USA	<b>Andrei Seferian</b> Le Kremlin-Bicêtre, France
<b>Felix Berger</b> Berlin, Germany	<b>Michael Gatzoulis</b> London, UK	<b>Walter Klepetko</b> Vienna, Austria	<b>Marc Simon</b> Pittsburgh, USA
<b>Stephen Chan</b> Pittsburgh, USA	<b>Ardeschir Ghofrani</b> Giessen, Germany	<b>Irene Lang</b> Vienna, Austria	<b>Gérald Simonneau</b> Le Kremlin-Bicêtre, France
<b>Richard Channick</b> Boston, USA	<b>Wendy Gin-Sing</b> London, UK	<b>Alessandra Manes</b> Bologna, Italy	<b>Olivier Sitbon</b> Le Kremlin-Bicêtre, France
<b>Martine Clozel*</b> Allschwil, Switzerland	<b>John Granton</b> Toronto, Canada	<b>Vallerie McLaughlin</b> Ann Arbor, USA	<b>Rogério Souza</b> Sao Paulo, Brazil
<b>Gerry Coghlan</b> London, UK	<b>Hong Gu</b> Beijing, China	<b>David Montani</b> Le Kremlin-Bicêtre, France	<b>Adam Torbicki</b> Otwock, Poland
<b>Marion Delcroix</b> Leuven, Belgium	<b>Sergio Harari</b> Milan, Italy	<b>Takeshi Ogo</b> Osaka, Japan	<b>Jean-Luc Vachiéry</b> Brussels, Belgium
<b>Gerhard Diller</b> Münster, Germany	<b>Marius M. Hoepfer</b> Hannover, Germany	<b>Horst Olschewski</b> Graz, Austria	<b>Anton Vonk Noordegraaf</b> Amsterdam, The Netherlands
<b>Kostas Dimopoulos</b> London, UK	<b>Luke Howard</b> London, UK	<b>Massimiliano Palazzini</b> Bologna, Italy	
<b>Daniel Dumitrescu</b> Cologne, Germany	<b>Marc Humbert</b> Le Kremlin-Bicêtre, France	<b>Ioana Preston</b> Boston, USA	

\*Chief Scientific Officer, Actelion Pharmaceuticals Ltd



This meeting is sponsored and organised by Actelion Pharmaceuticals Ltd  
Actelion Pharmaceuticals Ltd | Gewerbestrasse 16 | 4123 Allschwil | Switzerland  
Phone +41 61 565 65 65 | Fax +41 61 565 65 00 | [www.actelion.com](http://www.actelion.com)